Kiley Juergens Wealth Management LLC Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO)

Kiley Juergens Wealth Management LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 38.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 11,930 shares of the company’s stock after selling 7,594 shares during the quarter. Kiley Juergens Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,026,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S in the 2nd quarter worth $25,000. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $42,000. Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. Finally, M&R Capital Management Inc. increased its stake in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after buying an additional 297 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $78.74 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business’s 50 day moving average price is $97.76 and its 200-day moving average price is $116.89. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The stock has a market cap of $353.33 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.84 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.